Needham Reiterates Buy on Medtronic, Maintains $101 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 87.0%

Neg 0% Neu 87% Pos 0%

Needham analyst Mike Matson reiterates Medtronic (NYSE:MDT) with a Buy and maintains $101 price target.

Comments

No comments yet. Be the first!